Literature DB >> 6402412

Aspirin can inhibit gastric mucosal cyclo-oxygenase without causing lesions in rat.

M Ligumsky, E M Golanska, D G Hansen, G L Kauffman.   

Abstract

Dose-response relationships between aspirin-induced cyclo-oxygenase inhibition and gastric mucosal injury were studied in rats. Oral or parenteral aspirin, 25 mg/kg, inhibited prostaglandin generation by 87%-95% at 1, 3, and 6 h with no lesion formation. Aspirin, 100 mg/kg, inhibited prostaglandin generation by 95%-98% at 1, 3, and 6 h, but lesions were observed only when aspirin was given orally. Three-hour pretreatment with intraperitoneal aspirin, 12.5 mg/kg, did not enhance the mucosal injury caused by 10 mM acidified taurocholate, although prostaglandin generation was inhibited by 80%. Pretreatment with 25 mg/kg aspirin inhibited prostaglandin generation by 89% and was associated with significant mucosal injury by acidified taurocholate. We conclude that aspirin-induced 95% inhibition of gastric mucosal cyclo-oxygenase is not, by itself, sufficient to produce lesions and inhibition by greater than 80% is required to predispose the gastric mucosa to injury by otherwise mild irritants.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6402412

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  40 in total

Review 1.  Mechanisms of NSAID-induced gastroenteropathy.

Authors:  A H Price; M Fletcher
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 2.  Non-steroidal anti-inflammatory drug-induced gastropathy. Mechanisms and management.

Authors:  S Szabo; W F Spill; K D Rainsford
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Mar-Apr

Review 3.  Present status and strategy of NSAIDs-induced small bowel injury.

Authors:  Kazuhide Higuchi; Eiji Umegaki; Toshio Watanabe; Yukiko Yoda; Eijiro Morita; Mitsuyuki Murano; Satoshi Tokioka; Tetsuo Arakawa
Journal:  J Gastroenterol       Date:  2009-07-01       Impact factor: 7.527

Review 4.  A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity.

Authors:  T Mahmud; D L Scott; I Bjarnason
Journal:  Ann Rheum Dis       Date:  1996-04       Impact factor: 19.103

5.  Gastric motility is an important factor in the pathogenesis of indomethacin-induced gastric mucosal lesions in rats.

Authors:  S Ueki; K Takeuchi; S Okabe
Journal:  Dig Dis Sci       Date:  1988-02       Impact factor: 3.199

6.  Role of endogenous gastric mucosal prostaglandins in the formation of acute gastric mucosal lesions induced by aspirin, ethanol, HCl and CH3COOH.

Authors:  I Amioka; T Arima; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1987-06

7.  Enantiomers of flurbiprofen can distinguish key pathophysiological steps of NSAID enteropathy in the rat.

Authors:  T Mahmud; S Somasundaram; G Sigthorsson; R J Simpson; S Rafi; R Foster; I A Tavares; A Roseth; A J Hutt; M Jacob; J Pacy; D L Scott; J M Wrigglesworth; I Bjarnason
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

8.  Intestinal permeability and inflammation in patients on NSAIDs.

Authors:  G Sigthorsson; J Tibble; J Hayllar; I Menzies; A Macpherson; R Moots; D Scott; M J Gumpel; I Bjarnason
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

9.  NSAIDs: the emperor's new dogma?

Authors:  I Bjarnason; K Takeuchi; R Simpson
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

10.  Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE--famotidine or rebamipide in comparison by endoscopy).

Authors:  Jun-ichi Yamao; Eiryo Kikuchi; Masami Matsumoto; Masaki Nakayama; Tatsuichi Ann; Hideyuki Kojima; Akira Mitoro; Motoyuki Yoshida; Masaaki Yoshikawa; Hiroshi Yajima; Yoshizumi Miyauchi; Hiroshi Ono; Koichi Akiyama; Goro Sakurai; Yoshikazu Kinoshita; Ken Haruma; Yoshinori Takakura; Hiroshi Fukui
Journal:  J Gastroenterol       Date:  2007-02-06       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.